NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

3.1.15 NICE encourages consultees to make their individual submissions accessible – for example, by putting them on their own websites after they have sent their submission to NICE.

https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/technology-appraisal-processes-guide-sept-2014.pdf

Quote:
________________________________________
Consultation process

The Charity was asked to feed into the appraisal process as a consultee for DCVax®-L. We talked to patients diagnosed with a glioblastoma, carers, as well as patients who have received the treatment and then used our community's views to form The Charity's consultation response.

Those we asked unanimously reported an unmet need of treatments available on the NHS for patients diagnosed with a glioblastoma.

The people we talked to who have already received the treatment emphasised its promising effect on their quality of life.

Many patients noted little or next-to-no side-effects.

Others positively highlighted DCVax®-L as a treatment that works alongside a patient's immune system as opposed to the weakening of it by the current standard of treatment for glioblastomas.

The Charity will now form part of a NICE appraisal committee in early November where researchers, clinicians, patient representatives and relevant bodies will be brought together to discuss the treatment's suitability for uptake.

https://www.thebraintumourcharity.org/media-centre/news/policy-news/brain-tumour-charity-submits-dcvax-l-consultation/